GABRA5
Gamma-aminobutyric acid receptor subunit alpha-5
As of the edition of 20 October 2026, GABRA5 (gamma-aminobutyric acid receptor subunit alpha-5, UniProt P31644) has 26 drugs tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31644
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 23
- Disease areas
- Nervous system; Mental health; Cancer; Lungs and airways; Infections; Digestive system; Urinary and reproductive; Immune system
- Registered trials of its drugs
- 1,243
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 22 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 26 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Midazolam | Marketed | Phase 4 | none listed |
| Remimazolam | Marketed | Phase 4 | none listed |
| Lorazepam | Marketed | Phase 4 | none listed |
| Alprazolam | Marketed | Phase 4 | none listed |
| Eszopiclone | Marketed | Phase 4 | none listed |
| Diazepam | Marketed | Phase 4 | none listed |
| Clonazepam | Marketed | Phase 4 | none listed |
| Flumazenil | Marketed | Phase 4 | none listed |
| Zopiclone | Marketed | Phase 4 | none listed |
| Clobazam | Marketed | Phase 4 | none listed |
| Padsevonil | Stopped | Phase 3 | none listed |
| Triazolam | Marketed | Phase 4 | none listed |
12 of 26 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |